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Long non-coding ribonucleic acids (RNAs) are a novel class of RNAmolecules, which are increasingly recognized as important molec-ular players in solid and hematologic malignancies. Herein we
investigated whether long non-coding RNA expression is associated
with clinical and molecular features, as well as outcome of younger
adults (aged <60 years) with de novo cytogenetically normal acute
myeloid leukemia. Whole transcriptome profiling was performed in a
training (n=263) and a validation set (n=114). Using the training set, we
identified 24 long non-coding RNAs associated with event-free survival.
Linear combination of the weighted expression values of these tran-
scripts yielded a prognostic score. In the validation set, patients with
high scores had shorter disease-free (P<0.001), overall (P=0.002) and
event-free survival (P<0.001) than patients with low scores. In multivari-
able analyses, long non-coding RNA score status was an independent
prognostic marker for disease-free (P=0.01) and event-free survival
(P=0.002), and showed a trend for overall survival (P=0.06). Among mul-
tiple molecular alterations tested, which are prognostic in cytogenetical-
ly normal acute myeloid leukemia, only double CEBPA mutations,
NPM1 mutations and FLT3-ITD associated with distinct long non-cod-
ing RNA signatures. Correlation of the long non-coding RNA scores
with messenger RNA and microRNA expression identified enrichment
of genes involved in lymphocyte/leukocyte activation, inflammation
and apoptosis in patients with high scores. We conclude that long non-
coding RNA profiling provides meaningful prognostic information in
younger adults with cytogenetically normal acute myeloid leukemia. In
addition, expression of prognostic long non-coding RNAs associates
with oncogenic molecular pathways in this disease. clinicaltrials.gov
Identifier: 00048958 (CALGB-8461), 00899223 (CALGB-9665), and
00900224 (CALGB-20202).
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ABSTRACT
Introduction
Acute myeloid leukemia (AML) is a highly heterogeneous disease with regard to
genetic abnormalities and clinical course.1 The prognosis of adult AML is generally
poor. Only 40% of younger adult (aged <60 years) and
10% of older (aged ≥60 years) AML patients achieve long-
term survival.1 Currently, chromosomal aberrations2-4 and
recurrent gene mutations5-8 are considered the most reli-
able and reproducible prognostic markers in AML, and are
used in the clinic to identify patients at high risk of death
and to guide treatment. Aberrant levels of messenger RNA
(mRNA)9-11 and microRNA (miR) transcripts12,13 also have
prognostic significance, and efforts have been made to
incorporate gene-expression profiling into prognostic algo-
rithms.14-16 
Long non-coding RNAs (lncRNAs) are a novel class of
RNA molecules that are longer than 200 nucleotides, have
no protein coding potential and are either located within
the intergenic stretches of the genome or overlap (in sense
or antisense direction) protein coding genes.17,18 These
transcripts regulate key cellular functions, such as chromo-
some dosage compensation,19 imprinting,20 cell cycle pro-
gression,21 and differentiation.22 In cancer, individual
lncRNAs have been shown to play an important role in
malignant transformation.23-25 Despite the growing under-
standing of the biologic significance of deregulated
lncRNA expression in malignant diseases, the value of
these molecules as potential biomarkers in the clinical set-
ting has not been extensively studied.26,27 With regard to
cytogenetically normal AML (CN-AML), the prognostic
and biologic significance of lncRNAs in younger adult
patients remains unknown. Therefore, we analyzed, using
whole transcriptome sequencing (RNA-seq), the lncRNA
profiles of younger adults with de novo CN-AML, who
were comprehensively characterized with regard to
molecular abnormalities and outcome. Herein, we show
that lncRNA profiling provides independent prognostic
information in these patients. We also show that expres-
sion levels of prognostic lncRNAs correlate with distinct
mRNA and miR signatures, and provide insights into the
leukemogenic pathways that these lncRNAs potentially
regulate. 
Methods
Patients and treatment
Pretreatment bone marrow (BM) or blood samples were
obtained from a training (n=263) and a validation set (n=114) of
younger adult patients (aged 17-59 years) with de novo CN-AML,
who received intensive cytarabine/anthracycline-based first-line
therapy on Cancer and Leukemia Group B (CALGB)/Alliance for
Clinical Trials in Oncology (Alliance) trials and were alive 30 days
after initiation of treatment. Per protocol, no patient received allo-
geneic stem cell transplantation in first complete remission (CR).
Details regarding treatment protocols are provided in the Online
Supplementary Appendix. All patients provided written informed
consent, and all study protocols were in accordance with the
Declaration of Helsinki and approved by institutional review
boards at each center.
Cytogenetic and molecular analyses
Cytogenetic analyses were performed in CALGB/Alliance-
approved institutional laboratories and results confirmed by cen-
tral karyotype review.28 The diagnosis of normal karyotype was
based on at least 20 metaphase cells analyzed in BM specimens
subjected to short-term (24- or 48-hour) unstimulated cultures.
Targeted amplicon sequencing using the MiSeq platform
(Illumina) was used to analyze DNA samples for presence of gene
mutations that have been reported to associate with clinical out-
come of CN-AML patients (i.e., mutations in the ASXL1,
DNMT3A [R882 and non-R882], IDH1, IDH2 [R140 and R172],
NPM1, RUNX1, TET2 or WT1 genes, and FLT3-tyrosine kinase
domain [FLT3-TKD] mutations), as described previously.26,29 A
variant allele frequency of ≥10% was used as the cutoff to distin-
guish between mutated versuswild-type alleles of these genes. The
presence of mutations in the CEBPA gene and FLT3-internal tan-
dem duplications (FLT3-ITD) were evaluated using Sanger
sequencing30 and fragment analysis,31 as described previously.
Since only double CEBPA mutations are favorable prognostic
markers in CN-AML,32 we considered only this genotype as
mutated.
Transcriptome analyses
RNA samples of all studied patients (n=377) were analyzed
with total RNA sequencing (after depletion of ribosomal and mito-
chondrial RNA) using the Illumina HiSeq 2500 platform. Due to
RNA quality restrictions, a subset of 300 patients could be addi-
tionally analyzed with small RNA sequencing, for profiling of miR
expression. Further details are provided in the Online
Supplementary Appendix. To determine the expression status of
patients (i.e., high versus low expressers) with regard to prognostic
expression markers (e.g., BAALC), the median values of normal-
ized RNA sequencing reads were used as the cutoff.
Statistical analyses
Clinical endpoint definitions are given in the Online
Supplementary Appendix. Baseline demographic, clinical, and
molecular features were compared between patients with low and
those with high lncRNA scores (later on referred to as favorable
and unfavorable, see below), and between the training and valida-
tion sets using the Wilcoxon rank-sum and Fisher’s exact tests for
continuous and categorical variables, respectively.33 The estimated
probabilities of disease-free (DFS), overall (OS) and event-free sur-
vival (EFS) were calculated using the Kaplan–Meier method, and
the log-rank test evaluated differences between survival distribu-
tions.34 Cox proportional hazard models were used to calculate
hazard ratios (HR) for DFS, OS and EFS.33 Multivariable propor-
tional hazards models were constructed using a backward selec-
tion procedure. All statistical analyses were performed by The
Alliance Statistics and Data Center.
Results
Global expression of lncRNAs
To investigate the role of lncRNAs in AML, we first
identified all known lncRNAs which were present in the
transcriptomes of the younger CN-AML patients who
were studied (n=377). After exclusion of contaminating
ribosomal RNA molecules, we identified 22,166 non-cod-
ing RNA transcripts. According to the GENCODE v22
database,35 23% of these transcripts were categorized as
processed pseudogenes, 21% as intergenic/intervening
lncRNAs, 21% as antisense lncRNAs, 4% as sense intron-
ic/overlapping lncRNAs and 31% were classified as other
transcripts (e.g., as unitary pseudogenes, unprocessed
pseudogenes etc.; Figure 1).
Generation of a prognostic lncRNA score in the 
training set
To assess the prognostic significance of lncRNA expres-
sion in younger adults with CN-AML, we performed
exploratory analysis in a training set (n=263) of younger
CN-AML patients and used a separate patient cohort to
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validate our findings (validation set, n=114). Comparison
of clinical and molecular characteristics at diagnosis
between the training and validation sets showed that they
were relatively similar, with the exceptions that patients in
the training set had higher percentages of blood blasts
(P=0.03), were more frequently FLT3-TKD-positive
(P=0.02), and had higher ERG (P=0.01) and BAALC
(P=0.002) expression levels (Online Supplementary Table S1). 
We first identified all lncRNAs that were highly associ-
ated with EFS (P<10-6) in the training set by univariable
lncRNA expression in younger adults with CN-AML
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Table 1. Comparison of clinical and molecular characteristics by favorable and unfavorable long non-coding RNA (lncRNA) score in the validation
set of younger adults with cytogenetically normal acute myeloid leukemia.
Characteristic Favorable Unfavorable P
lncRNA  Score lncRNA
(n=57) Score (n=57)
Age, years 0.44
Median 44 47 
Range 18-59 18-59
Sex, n. (%) 1.00
Male 28 (49) 29 (51)
Female 29 (51) 28 (49)
Race, n. (%) 1.00
White 51 (91) 50 (89)
Non-white 5 (9) 6 (11)
Hemoglobin (g/dL) 0.66
Median 9.1 8.8
Range 4.2-25.1 4.8-13.4
Platelet count (x109/L) 0.49
Median 52 55 
Range 10-271 8-433
WBC count (x109/L) 0.009
Median 24.9 45.7 
Range 0.9-475.0 2.2-295.0
Blood blasts, % 0.06
Median 45 63 
Range 0-90 0-97
Bone marrow blasts, % 0.25
Median 63 68 
Range 21-91 18-95
Extramedullary involvement, n. (%) 15 (28) 18 (32) 0.68
Autologous HCT in 1st CR, n. (%) 33 (65) 23 (48) 0.11
NPM1, n. (%) 1.00
Mutated 37 (65) 37 (65)
Wild-type 20 (35) 20 (35)
FLT3-ITD, n. (%) 0.007
Present 15 (27) 30 (54)
Absent 40 (73) 26 (46)
CEBPA, n. (%) 0.78
Double Mutated 8 (15) 6 (12)
Wild-type 46 (85) 45 (88)
FLT3-TKD, n. (%) 0.36
Present 4 (7) 1 (2)
Absent 51 (93) 54 (98)
WT1, n. (%) 0.09
Mutated 4 (7) 10 (19)
Wild-type 52 (93) 44 (81)
TET2, n. (%) 0.49
Mutated 6 (11) 3 (6)
Wild-type 50 (89) 51 (94)
IDH1, n. (%) 1.00
Mutated 4 (7) 3 (5)
Wild-type 52 (93) 52 (95)
IDH2, n. (%) 1.00
Mutated 7 (13) 6 (11)
R140 4 6
R172 3 0
Wild-type 49 (88) 49 (89)
ASXL1, n. (%) 1.00
Mutated 2 (4) 1 (2)
Wild-type 54 (96) 51 (98) continued in the next page
Cox analysis (Figure 2). EFS was used because it compre-
hensively evaluates the lncRNAs that are associated with
response to chemotherapy, probability of relapse and
probability of survival. We detected 24 lncRNAs associat-
ed with EFS (P<10-6; Online Supplementary Table S2). Next,
we derived a prognostic lncRNA score by linear combina-
tion of the weighted expression values of these 24
lncRNAs. The median value of the lncRNA score was used
to dichotomize the training set of patients. Patients with
low lncRNA scores (n=132) had longer DFS (P<0.001), OS
(P<0.001) and EFS (P<0.001) than patients with high
lncRNA scores (n=131). We therefore classified low
lncRNA scores as “favorable” and high as “unfavorable”
(Online Supplementary Table S3 and Online Supplementary
Figure S1). 
Association of lncRNA score with patient 
characteristics and clinical outcome in the training set
With regard to clinical and molecular characteristics,
patients with favorable lncRNA scores in the training set
were more likely to present with higher hemoglobin lev-
els (P=0.02), lower white blood cell (WBC) counts
(P<0.001), and lower percentages of BM blasts (P=0.02).
They were also less likely to harbor FLT3-ITD (P<0.001),
DNMT3A (P=0.01) and RUNX1 (P=0.009) mutations and
more likely to harbor double CEBPA mutations
(P<0.001). Patients with favorable lncRNA scores in the
training set differed with regard to their distribution in
the Risk Categories of the European LeukemiaNet (ELN)
classification of AML,1 when compared with patients
with unfavorable lncRNA scores (P<0.001); patients with
favorable lncRNA scores were more frequently classified
as favorable and less frequently as intermediate or
adverse risk than those with unfavorable lncRNA scores
(Online Supplementary Table S4). Favorable lncRNA score
status also associated with high expression of miR-181a
(P<0.001) and low expression of miR-155 (P=0.03, Online
Supplementary Table S4). Association of a favorable
lncRNA score with longer DFS, OS and EFS remained
significant in multivariable analyses (P<0.001 for all 3
end points, Online Supplementary Table S5), after adjusting
for other co-variates.
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Characteristic Favorable Unfavorable P
lncRNA  Score lncRNA
(n=57) Score (n=57)
DNMT3A, n. (%) 0.56
Mutated 20 (36) 23 (43)
R882 14 20
Non-R882 6 3
Wild-type 36 (64) 31 (57)
RUNX1, n. (%) 1.00
Mutated 3 (5) 2 (4)
Wild-type 53 (95) 52 (96)
ELN Risk Category,* n. (%) 0.02
Favorable 37 (71) 23 (43)
Intermediate 11 (21) 20 (38)
Adverse 4 (8) 10 (19)
ERG expression group,† n. (%) 0.85
High 22 (39) 23 (41)
Low 35 (61) 33 (59)
BAALC expression group,† n. (%) 0.84
High 19 (36) 21 (39)
Low 34 (64) 33 (61)
MN1 expression group,† n. (%) 0.06
High 18 (33) 29 (52)
Low 37 (67) 27 (48)
miR-181a expression group,† n. (%) 0.41
High 24 (50) 18 (40)
Low 24 (50) 27 (60)
miR-3151, n. (%) 0.36
Expressed 8 (17) 4 (9)
Not expressed 40 (83) 41 (91)
miR-155 expression group,† n. (%) <0.001
High 16 (33) 31 (69)
Low 32 (67) 14 (31)
*Among patients with cytogenetically normal acute myeloid leukemia (CN-AML), the ELN favorable risk category comprises patients with double-mutated CEBPA and patients
with mutated NPM1 without FLT3-ITD or with FLT3-ITDlow. The ELN intermediate risk category includes patients with wild-type NPM1 without FLT3-ITD or wild-type NPM1 and
FLT3-ITDlow or mutated NPM1 and FLT3-ITDhigh. The ELN adverse risk category comprises patients with wild-type NPM1 and FLT3-ITDhigh and/or mutated RUNX1 (if it does not co-
occur with a favorable AML subtype) and/or mutated ASXL1 (if does not co-occur with a favorable AML subtype) and/or mutated TP53. FLT3-ITDlow is defined by a FLT3-ITD/FLT3
wild-type allelic ratio of less than 0.5 and FLT3-ITDhigh is defined by a FLT3-ITD/FLT3 wild-type allelic ratio of equal to or more than 0.5.1 †The median expression value was used
as the cut point. WBC: white blood cell; HCT: hematopoietic cell transplant; CR: complete remission; ELN: European LeukemiaNet; FLT3-ITD: internal tandem duplication of the
FLT3 gene; FLT3-TKD: tyrosine kinase domain mutation in the FLT3 gene; lncRNA: long non-coding ribonucleic acid; miR: microRNA.
continued in the previous page
Association of lncRNA score with patient 
characteristics and clinical outcome in the validation
set
We used the median value of the lncRNA score, as cal-
culated in the training set to divide the validation set into
favorable and unfavorable lncRNA score groups (Figure 2).
Patients with favorable lncRNA scores (n=57) were less
likely to present with higher WBC counts at the time of
diagnosis (P=0.009) or to harbor FLT3-ITD (P=0.007).
lncRNA score status also associated with significantly dif-
ferent distribution of the patients in the Risk Categories of
the ELN guidelines (P=0.02).1 Patients with favorable
lncRNA scores were more likely to belong to the favorable
and less likely to belong to the intermediate or adverse risk
category. Patients with favorable lncRNA scores in the val-
idation set were less likely to be miR-155 high-expressers
(P<0.001) than patients with unfavorable lncRNA scores
(n=57; Table 1).
Patients with favorable lncRNA scores had longer DFS
than those with unfavorable lncRNA scores (P<0.001;
Figure 3A). Five years after diagnosis, 51% of patients
with favorable lncRNA scores remained alive and
leukemia-free, in contrast to only 17% of those with unfa-
vorable lncRNA scores. Favorable lncRNA score status
also associated with longer OS (P=0.002, 5-year rates,
52% versus 26%; Figure 3B) and longer EFS (P<0.001, 5-
year rates, 46% versus 16%; Figure 3C, Online
Supplementary Table S6). The prognostic value of the
lncRNA score in the validation set remained significant
when it was analyzed as a continuous variable.
Increasingly favorable lncRNA scores associated with
longer DFS (P<0.001), OS (P=0.007) and EFS (P=0.002).
In multivariable analyses, favorable lncRNA score status
was an independent marker for longer DFS (P=0.01), after
adjusting for miR-155 expression status, and EFS
(P=0.002), after adjusting for the presence of FLT3-ITD
(Table 2). With regard to OS, patients with a favorable
lncRNA score had a trend for longer survival (P=0.06),
after adjustment for FLT3-ITD and MN1 expression status.
Associations of recurrent gene mutations with lncRNA
expression
We evaluated if recurrent prognostic gene mutations in
CN-AML associated with distinct expression patterns of
lncRNAs in younger adults with CN-AML. For this pur-
pose, mutation-related lncRNA signatures were derived in
the training set using stringent criteria (for details see
Methods and the Online Supplementary Appendix).
Double-mutated CEBPA showed the strongest associa-
tion with lncRNA expression; 82 lncRNAs were upregulat-
ed and 186 lncRNAs were downregulated in patients who
harbored double-mutated CEBPA (Figure 4A, Online
Supplementary Table S7). Among the CEBPA mutation-
related lncRNAs, NEAT1was significantly underexpressed
in the group of patients with CEBPA mutations. This
lncRNA has been involved in myeloid differentiation of
acute promyelocytic leukemia cells after all-trans retinoic
acid treatment.36
Mutations in the NPM1 gene also strongly associated
with a lncRNA signature, which comprised 35 transcripts
upregulated and 37 transcripts downregulated in patients
harboring NPM1 mutations (Figure 4B, Online
Supplementary Table S8). Thirty-three of the 35 lncRNAs
overexpressed in patients with NPM1 mutations, were
downregulated in patients with CEBPA mutations. This
finding is consistent with the observation that double
CEBPA and NPM1mutations rarely co-occur in CN-AML.
NPM1 mutations were positively associated with
lncRNAs embedded within the HOX gene loci (HOXA-
AS3, HOXB-AS3) and other lncRNAs implicated in
myelopoiesis (EGOT137) or carcinogenesis (e.g., PCAT1838
and LUCAT139).
The FLT3-ITD-related lncRNA signature consisted of 26
transcripts, 19 of which were upregulated and 7 downreg-
ulated in patients with this mutation (Figure 4C, Online
Supplementary Table S9). The host gene of miR-155
(MIR155HG) was among the lncRNAs overexpressed in
FLT3-ITD-positive patients. High MIR155HG expression
independently associates with poor outcome in CN-
lncRNA expression in younger adults with CN-AML
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Figure 1. Distribution of the 22,166
detected non-coding RNA transcripts
among different classes of non-cod-
ing RNA molecules. Annotation of
transcripts was performed according
to the GENCODE v22 database.
lncRNA indicates long non-coding
RNA and lincRNA denotes long inter-
genic/intervening non-coding RNA.
*Other refers to: microRNAs, miscel-
laneous non-coding RNAs,
unprocessed pseudogenes, small
RNAs, translated unprocessed
pseudogenes, processed transcripts,
small nucleolar RNAs, transcribed
processed pseudogenes, T-cell
receptor pseudogenes, immunoglob-
ulin genes, immunoglobulin pseudo-
genes, unitary pseudogenes, small
cajal body specific RNAs, polymor-
phic pseudogenes, 3-prime overlap-
ping non-coding RNAs, transcribed
unitary pseudogenes and macro
lncRNAs. lncRNA: long non-coding
ribonucleic acid.
AML.40 The WT1-AS lncRNA was also highly expressed
among FLT3-ITD-positive patients; it has been reported to
post-translationally regulate the protein levels of WT1.41
To assess the capacity of gene mutation-related lncRNA
signatures to detect their corresponding molecular alter-
ations in CN-AML patients, we applied these signatures to
the validation set. The mutated CEBPA-related signature
showed the highest level of accuracy (specificity and sen-
sitivity of mutated CEBPA detection: ≥93% and ≥98%,
respectively), followed by the mutated NPM1-related
(sensitivity: ≥80%, specificity ≥73%) and the FLT3-ITD-
related signatures (sensitivity ≥70%, specificity: ≥76%).
The remaining prognostic gene mutations that were tested
either did not associate with differential expression of
lncRNAs (i.e., TET2 mutations) or generated signatures
that failed to reliably detect the mutational status of
patients in the validation set (e.g., DNMT3A, WT1 muta-
tions).
Biologic implications of the lncRNA score
To gain biologic insights into the molecular pathways
that may be affected by differences in the lncRNA score,
we examined the correlation between the lncRNA score
and the mRNA/miRNA expression in 300 younger CN-
AML patients who had available mRNA and miRNA pro-
filing data. 
We identified 410 mRNA transcripts whose expression
levels correlated with the lncRNA score, 172 of which cor-
related positively and 238 negatively with unfavorable
lncRNA scores (Figure 5A, Online Supplementary Table S10).
Among highly expressed genes in patients with unfavor-
able lncRNA scores, putative oncogenes and key media-
tors of the oncogenic AP-1 pathway such as ATF3, FOS,
FOSB, JUN, and MAFF were identified. With regard to
hematopoiesis, the AP-1 pathway has been shown to reg-
ulate proliferation of erythroleukemia cells,42 to mediate
monocyte/macrophage differentiation of myeloid cells43
and to co-regulate miR-155 expression in stimulated
macrophages.44 Genes that regulate immune responses
(e.g., IL1B, IRF7, CD80) and genes that mediate immune
evasion (e.g., IER3, LILRB4) were also highly expressed in
patients with unfavorable lncRNA profiles. Finally, onco-
genes promoting proliferation of malignant cells (e.g., RET,
ETS2, PLK2, NEK6, PLK3 and SRC) were found to be
overexpressed in patients with unfavorable lncRNA
scores. Gene ontology analysis revealed that genes
involved in lymphocyte/leukocyte activation, inflamma-
tion, response to wounding and regulation of apoptosis
were enriched in the subset of patients with unfavorable
lncRNA scores (Figure 5B, Online Supplementary Table S11).
Among mRNA molecules downregulated in patients
with unfavorable lncRNA scores, we detected transcripts
with reported tumor-suppressive function (APC, JADE1,
BRMS1L, and ING3). Gene ontology analysis showed that
genes that participate in the regulation of transcription,
the regulation of RNA metabolic processes and DNA
binding were underexpressed in the group of patients
with unfavorable lncRNA scores (Figure 5C, Online
Supplementary Table S11).
With regard to miR expression, 10 miRs were found to
correlate positively (miR-660, miR-502, miR-532-5p, miR-
155, miR-500a-3p, miR-500a-5p, miR-532-3p, miR-362,
miR-339 and miR-23a) and 4 miRs to correlate negatively
(miR-192, miR-625, miR-100 and miR-194) with unfavor-
able lncRNA scores (Online Supplementary Table S12).
Among the 10 miRs that positively correlated with unfa-
vorable lncRNA scores, 7 were located in close proximity
on chromosome X; miR-660, miR-502, miR-532-5p, miR-
500a-3p, miR-500a-5p, miR-532-3p and miR-362 are all
imbedded in intron 3 of the CLCN5 gene. This miR cluster
mediates an anti-apoptotic effect in chronic lymphocytic
leukemia cells.45 miR-155, which also positively correlated
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Figure 2. Overview of the study design.
with unfavorable lncRNA scores, is an established adverse
prognosticator in CN-AML40 and has been implicated in
leukemogenesis of FLT3-ITD-positive AML.46
Discussion
Over the past 5 years, lncRNAs have emerged as new
players in cancer biology and biomarker discovery.47 Our
group has previously reported that distinctive lncRNA sig-
natures are associated with prognostic gene mutations in
older CN-AML patients, and that expression levels of a
small group of lncRNAs have prognostic significance in
these patients.26 Since CN-AML in younger adults differs
with regard to clinical features, associated molecular
abnormalities and outcome from that in older patients, we
investigated the prognostic value and biologic implica-
tions of lncRNA expression in a total of 377 CN-AML
adult patients younger than 60 years.
First, we identified 24 lncRNAs highly correlated with
EFS. Similarly to the previously reported older CN-AML
patients,26 only a small number of these prognostic
lncRNAs associated with prognostic gene mutations:
MIR155HGwas upregulated in patients who harbor FLT3-
ITD, AC006129.2was upregulated in patients with double
CEBPA mutations, whereas AL122127.25, RP11-946L16.2,
lncRNA expression in younger adults with CN-AML
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Table 2. Multivariable analyses for outcome in the validation set of younger adults with cytogenetically normal acute myeloid leukemia.
Variables in final models Disease-free survival Overall survival Event-free survival
HR (95% CI) P HR (95% CI) P HR (95% CI) P
lncRNA score, favorable versus unfavorable 0.46 (0.26-0.83) 0.01 0.6 (0.35-1.03) 0.06 0.48 (0.30-0.77) 0.002
miR-155, high versus low* 1.81 (1.01-3.24) 0.05 - - - -
FLT3-ITD, present versus absent - - 1.96 (1.17-3.29) 0.01 2.15 (1.36-3.41) 0.001
MN1, high versus low* - - 1.92 (1.16-3.17) 0.01 - -
Hazard ratios greater than (less than) 1.0 indicate higher (lower) risk for relapse or death (disease-free survival) or death (overall survival) or for failure to achieve complete
remission, relapse or death (event-free survival) for the first category listed. Variables considered for model inclusion were: lncRNA score status (favorable versus unfavorable),
age (as a continuous variable, in 10-year increments), sex (male versus female), race (white versus non-white), white blood cell count (as a continuous variable, in 
50-unit increments), hemoglobin (as a continuous variable, in 1-unit increments), platelet count (as a continuous variable, in 50-unit increments), extramedullary involvement
(present versus absent), ASXL1mutations (mutated versuswild-type), CEBPAmutations (double-mutated versus single-mutated or wild-type), DNMT3Amutations (mutated versus
wild-type), FLT3-ITD (present versus absent), FLT3-TKD (present versus absent), IDH1 mutations (mutated versus wild-type), IDH2 mutations (mutated versus wild-type), NPM1
mutations (mutated versus wild-type), RUNX1 mutations (mutated versus wild-type), TET2 mutations (mutated versus wild-type), WT1 mutations (mutated versus wild-type),
BAALC expression levels (high versus low), ERG expression levels (high versus low),  MN1 expression levels (high versus low), miR-181a expression levels (high versus low), miR-
3151 (expressed versus not expressed), and miR-155 expression levels (high versus low). * The median expression value was used as the cut point. HR: hazard ratio; CI: confidence
interval; lncRNA: long non-coding RNA; FLT3-ITD: internal tandem duplication of the FLT3 gene.
Figure 3. Outcomes of younger adult patients with cyto-
genetically normal acute myeloid leukemia with favor-
able and unfavorable long non-coding RNA (lncRNA)
scores in the validation set. (A) Disease-free survival, (B)
overall survival and (C) event-free survival. The lncRNA
score of each individual patient was computed as a
weighted score of 24 prognostic lncRNAs.
A
C
BP<0.001
P<0.001
P=0.002
SDHAP3 and SENC3 were downregulated in patients
with double CEBPA mutations. Of the 24 prognostic
lncRNA genes, only MIR155HG has previously been asso-
ciated with the clinical outcome of CN-AML patients.40,48
Linear combination of the weighted expression values
of lncRNA transcripts yielded a prognostic score, which
strongly associated with DFS, EFS and OS duration in
younger adult CN-AML patients. Favorable lncRNA score
status was an independent marker for longer DFS and EFS
(and also showed a strong trend towards significance for
longer OS). We were intrigued to find no overlap between
the 48 prognostic lncRNAs that we previously identified
in older CN-AML patients26 and the 24 transcripts reported
herein in younger patients. This finding could be interpret-
ed as an additional biologic difference between CN-AML
of younger and that of older patients, similar to the age-
dependent difference in frequency of some recurrent prog-
nostic gene mutations (e.g., mutations in the ASXL1 and
RUNX1 genes).1
We also examined the associations between recurrent
prognostic gene mutations and lncRNA expression, and
found double CEBPA and NPM1 mutations and FLT3-ITD
to associate with distinct lncRNA signatures. We identi-
fied several lncRNAs that were commonly associated with
these gene mutations in both younger and older CN-AML
patients26 (e.g., the HOX-loci embedded lncRNAs in the
NPM1mutation-related lncRNA signature, WT1-AS in the
FLT3-ITD-related signature, etc.). On the other hand, such
gene mutations as RUNX1 and ASXL1 that are more fre-
quent in older CN-AML patients and were found to asso-
ciate with differential expression of lncRNAs26 could not
be tested in younger CN-AML patients, because too few
younger patients harbored these mutations. Of note,
mutations in the TET2 gene showed no correlation with
differential expression of lncRNA molecules in either
older26 or younger CN-AML patients, despite their impact
on the epigenome49 and adequate numbers of patients in
both studied cohorts.
To gain insights into biologic pathways affected by differ-
ences in the lncRNA score, we investigated correlations
between mRNA and miR expression signatures and
lncRNA scores. In concordance with the adverse outcome
that unfavorable lncRNA scores bestow, a number of previ-
ously described oncogenes and oncomiRs were found over-
expressed in patients with unfavorable lncRNA score status.
Similarly, genes with reported tumor-suppressive activity
were found downregulated in this patient group. Only a
small fraction of these transcripts have been reported in
gene mutation-related mRNA signatures or other prognos-
tic gene-expression signatures.14-16 These findings indicate
that, in addition to being independent of prognostic muta-
tions, the differential expression of prognostic lncRNAs
may regulate distinct molecular pathways in CN-AML.
Notably, 5 important mediators of the AP-1 pathway (ATF3,
FOS, FOSB, JUN, and MAFF) were found upregulated in
patients with unfavorable lncRNA scores. The high number
of cell cycle regulators and proliferation-inducing kinases
that were also upregulated in this patient group is consis-
tent with aberrant activation of the AP-1 pathway.
In this work, we used whole transcriptome sequencing
techniques to identify and measure the expression of
prognostic lncRNA molecules in younger adults with CN-
AML. While this technology is becoming rapidly cheaper
and widely available, it will most likely continue to serve
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Figure 4. Long non-coding RNA (lncRNA) expression signatures associated with prognostic gene mutations in younger adult patients with cytogenetically normal
acute myeloid leukemia. Heat maps for (A) double CEBPA, (B) NPM1 and (C) FLT3-ITD mutation-related lncRNA signatures are presented. The lncRNA signatures
were derived in the training set of the studied cohort. Expression values of the lncRNA transcripts are represented by color, with green indicating expression less
than and red indicating expression greater than the median value for the lncRNA transcript. Gray color indicates lack of detectable expression. Rows represent
lncRNA transcripts, and columns represent patients. Patients are grouped by the gene mutational status (i.e., mutated [mut] versus wild-type [wt]). For a full list of
the lncRNAs that associated with prognostic gene mutations see the Online Supplementary Appendix.
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as a research tool rather than a diagnostic test to guide
patient treatment. Despite this, alternative techniques for
measuring RNA transcripts in a clinically applicable man-
ner are available and are used to risk stratify patients with
certain solid malignancies.50 Similar assays could be devel-
oped in order to obtain targeted measurements of prog-
nostic lncRNAs in a fast and clinically meaningful manner.
The potential of such assays to improve risk stratification
of AML patients should be evaluated in future prospective
clinical studies. 
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Figure 5. Messenger RNA (mRNA) transcripts which associate with the long non-coding RNA (lncRNA) score in younger adults with cytogenetically normal acute
myeloid leukemia (CN-AML). (A) Heat map of the gene-expression signature associated with the lncRNA score. Rows represent protein-coding genes and columns
represent patients. Patients are grouped by lncRNA score: favorable on the left and unfavorable on the right. The lncRNA score of each individual patient was com-
puted as a weighted score of 24 prognostic lncRNAs. Expression values of the lncRNA transcripts are represented by color: green: expression less than median value;
red: expression greater than median value; gray: lack of detectable expression. Top 5 gene ontology terms that positively (B) or negatively (C) correlate with unfavor-
able lncRNA scores in younger patients with CN-AML are displayed. Gene ontology terms in (B) and (C) are ranked according to fold enrichment. 
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